Metformin

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, Regeneration, Learning, Glycated hemoglobin, Menin, C-peptide, Insulin, Diabetes, AUC, Patient, Fasting, MD, Metformin, Person, Cancer, Safety, A1C, DSM-IV codes, Pharmaceutical industry

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).

Key Points: 
  • “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
  • Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
  • The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

L-Nutra's Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology

Retrieved on: 
Thursday, April 4, 2024
Glycated hemoglobin, Metabolism, FMD, Type 2 diabetes, Disease, Insulin, Diabetes, Patient, Research, Fasting, Standard of care, Food, Doctor of Philosophy, Diet, Insulin resistance, Clinical trial, Type 2, Safety, Waist, BMI, Metformin, Movement, Prediabetes, Pharmaceutical industry

This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.

Key Points: 
  • This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.
  • Glycemic Management: FMD participants demonstrated superior glycemic management, with 53% showing improvement, compared to only 8% in the control group.
  • L-Nutra's patented and clinically backed nutrition technology food formulations are effective in supporting metabolism, cell renewal, and muscle protection by mimicking the reset and rejuvenation pathways of fasting.
  • "With the Fasting Mimicking Diet, we have successfully enhanced the natural rejuvenating power of fasting with food which has made the regression and remission of diabetes within every patient's reach.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Friday, March 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

The curious link between animal hibernation and ageing – and what humans could learn from it

Retrieved on: 
Friday, January 5, 2024
Animal, Hibernation, Onion, Bread, Dementia, Protein, Metabolism, Life, Glass, Envy, Farmer, Man, Health, Metformin, Organ transplantation, DNA, Medical journal, Inflammation, Chronic kidney disease, Elephant, Lifestyle, Water, Type, Obesity, Food, The BMJ, Gene, Sleep, Radical, Oxidative stress, Longevity, Growth, Patient, Cardiovascular disease, Nature, Deficit spending, History, Flavonoid, Hunting

This long, deep rest is an example of how nature develops clever solution to difficult problems.

Key Points: 
  • This long, deep rest is an example of how nature develops clever solution to difficult problems.
  • In this case, how to survive a long, cold and dark period without much food and water.
  • You will also find descriptions in Inuit Greenlandic stories of a prolonged hibernation-like sleep during the long dark winter months.

Animals and hibernation

  • Animals that hibernate usually live longer compared to other species of the same size.
  • Recent studies using epigenetic clocks, which map activity within genes over time, suggest that hibernation slows down ageing in marmots and bats.
  • So hibernation may hold important clues on how to slow down ageing processes.
  • New science based on epigenetic clocks and lessons from hibernating animals could help us to treat patients who have diseases driven by “wear and tear”.
  • A 2018 study found that mimicking hibernation conditions for the storage of renal grafts from deceased donors seemed to improve their preservation.

Animals and longevity

  • It seems like protection against inflammation, oxidative stress and modifications of proteins that happen with age are mechanism that in general benefit all long-lived animals.
  • Genetic studies of rougheye rockfish, which can live for over 200 years, suggest that a food group called flavonoids is related to longevity.
  • Lessons from nature and hibernating animals tell us that preserving cells, regulation metabolism and genetic adaptions play key roles in longevity.

Forty winks

  • For example, a March 2023 study showed that with good quality sleep, you can add five years to the life of men and two and a half years if you are a woman.
  • How elephants can become so old while sleeping so little is still a mystery to scientists.


Peter Stenvinkel receives funding from Astra Zeneca, Fresenius, Baxter, Novo Nordisk, Bayer, Invizius, Vifor for lectures and scientific advisory boards

What humans can learn from animals about how to adapt to winter

Retrieved on: 
Friday, January 5, 2024
Animal, Hibernation, Onion, Bread, Dementia, Protein, Metabolism, Life, Glass, Envy, Farmer, Man, Health, Metformin, Organ transplantation, DNA, Medical journal, Inflammation, Chronic kidney disease, Elephant, Lifestyle, Water, Type, Obesity, Food, The BMJ, Gene, Sleep, Radical, Oxidative stress, Longevity, Growth, Patient, Cardiovascular disease, Nature, Deficit spending, History, Flavonoid, Hunting

When the cold and dark winter is setting in, some of us envy animals that can hibernate.

Key Points: 
  • When the cold and dark winter is setting in, some of us envy animals that can hibernate.
  • In this case, how to survive a long, cold and dark period without much food and water.
  • You will also find descriptions in Inuit Greenlandic stories of a prolonged hibernation-like sleep during the long dark winter months.

Animals and hibernation

  • Animals that hibernate usually live longer compared to other species of the same size.
  • Recent studies using epigenetic clocks, which map activity within genes over time, suggest that hibernation slows down ageing in marmots and bats.
  • So hibernation may hold important clues on how to slow down ageing processes.
  • New science based on epigenetic clocks and lessons from hibernating animals could help us to treat patients who have diseases driven by “wear and tear”.
  • A 2018 study found that mimicking hibernation conditions for the storage of renal grafts from deceased donors seemed to improve their preservation.

Animals and longevity

  • It seems like protection against inflammation, oxidative stress and modifications of proteins that happen with age are mechanism that in general benefit all long-lived animals.
  • Genetic studies of rougheye rockfish, which can live for over 200 years, suggest that a food group called flavonoids is related to longevity.
  • Lessons from nature and hibernating animals tell us that preserving cells, regulation metabolism and genetic adaptions play key roles in longevity.

Forty winks

  • For example, a March 2023 study showed that with good quality sleep, you can add five years to the life of men and two and a half years if you are a woman.
  • How elephants can become so old while sleeping so little is still a mystery to scientists.


Peter Stenvinkel receives funding from Astra Zeneca, Fresenius, Baxter, Novo Nordisk, Bayer, Invizius, Vifor for lectures and scientific advisory boards